Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib for SqNSCLC with Cell Cycle Gene Alterations (Lung-Map S1400C)
NCT02785939Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in squamous cell carcinoma of the lung (LSCC) (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Objective Response Rate. Started Sep 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02785939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785939.